Nitric oxide (NO) is now considered an important biomarker for respiratory disease. Studies have confirmed that the fractional concentration of exhaled nitric oxide (FENO) is elevated in the airways of patients who have asthma in comparison with controls. The level of FENO correlates well with the presence and level of inflammation, and decreases with glucocorticoid treatment. NO has potential to be used not only as a diagnostic aid but also as a management tool for assessing severity, monitoring response to therapy, and gaining control of asthma symptoms. This article reviews the biology of NO and its role in respiratory disease.
机构:
Manchester Univ NHS Fdn Trust, NIHR Manchester Clin Res Facil, Manchester, Lancs, EnglandManchester Univ NHS Fdn Trust, NIHR Manchester Clin Res Facil, Manchester, Lancs, England
Bikov, Andras
Meszaros, Martina
论文数: 0引用数: 0
h-index: 0
机构:
Semmelweis Univ, Dept Pulmonol, Budapest, HungaryManchester Univ NHS Fdn Trust, NIHR Manchester Clin Res Facil, Manchester, Lancs, England
Meszaros, Martina
Lazar, Zsofia
论文数: 0引用数: 0
h-index: 0
机构:
Semmelweis Univ, Dept Pulmonol, Budapest, HungaryManchester Univ NHS Fdn Trust, NIHR Manchester Clin Res Facil, Manchester, Lancs, England